
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in a subset of early-stage breast cancer patients. The phase 3 DESTINY-Breast11 …